Ariel Grajales-Cruz, MD, discusses the rationale for a real-world study of teclistamab in patients with myeloma who had received BCMA-directed therapy.
Ariel Grajales-Cruz, MD, discusses real-world safety and efficacy outcomes from treatment with the bispecific antibody teclistamab in heavily pretreated patients with relapsed/refractory multiple myeloma who progressed on a prior BCMA-directed therapy.